PL2576624T3 - Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznych - Google Patents

Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznych

Info

Publication number
PL2576624T3
PL2576624T3 PL11786091T PL11786091T PL2576624T3 PL 2576624 T3 PL2576624 T3 PL 2576624T3 PL 11786091 T PL11786091 T PL 11786091T PL 11786091 T PL11786091 T PL 11786091T PL 2576624 T3 PL2576624 T3 PL 2576624T3
Authority
PL
Poland
Prior art keywords
treatment
recombinant human
neurological diseases
csf dimer
csf
Prior art date
Application number
PL11786091T
Other languages
English (en)
Inventor
Xiaoqiang Yan
Zhihua Huang
Hongzhou Yang
Bill N.C. Sun
Yuliang Huang
Original Assignee
Generon (Shanghai) Corporation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon (Shanghai) Corporation Ltd. filed Critical Generon (Shanghai) Corporation Ltd.
Publication of PL2576624T3 publication Critical patent/PL2576624T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11786091T 2010-05-25 2011-05-25 Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznych PL2576624T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101816235A CN102260343A (zh) 2010-05-25 2010-05-25 重组人g-csf二聚体在治疗神经损伤疾病中的用途

Publications (1)

Publication Number Publication Date
PL2576624T3 true PL2576624T3 (pl) 2017-02-28

Family

ID=45003325

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11786091T PL2576624T3 (pl) 2010-05-25 2011-05-25 Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznych

Country Status (15)

Country Link
US (2) US8557546B2 (pl)
EP (2) EP2576624B1 (pl)
JP (1) JP6114186B2 (pl)
CN (3) CN102260343A (pl)
AU (1) AU2011257734B2 (pl)
CA (1) CA2800688C (pl)
DK (2) DK3121198T3 (pl)
ES (2) ES2611151T3 (pl)
FI (1) FIC20240027I1 (pl)
FR (1) FR24C1032I2 (pl)
HU (2) HUE031872T2 (pl)
NL (1) NL301285I2 (pl)
PL (1) PL2576624T3 (pl)
PT (1) PT2576624T (pl)
WO (1) WO2011147319A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
CN103717614A (zh) * 2011-08-09 2014-04-09 普罗法尔马封闭式股份公司 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
LT6161B (lt) * 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
EP2957294A1 (en) * 2014-06-20 2015-12-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. GCSF for use in the treatment of neurogenic immune suppression and/or prevention of related medical complications
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
US20260053742A1 (en) 2022-08-19 2026-02-26 Evive Biotechnology (Shanghai) Ltd Formulations comprising g-csf and uses thereof
AU2024309736A1 (en) 2023-06-30 2026-01-15 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954004B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000024758A1 (en) 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
GB0024442D0 (en) 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
CN100515491C (zh) 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2008137571A1 (en) 2007-05-01 2008-11-13 Florida Atlantic University Methods of treating neurodegenerative diseases
WO2008147534A1 (en) 2007-05-22 2008-12-04 Maxygen Holdings Ltd. Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
EP2185583A2 (en) 2007-08-03 2010-05-19 Asterion Limited Granulocyte colony stimulating factor
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
KR101867606B1 (ko) 2007-11-07 2018-06-18 제넨테크, 인크. 미생물 질환의 치료를 위한 조성물 및 방법
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
AU2011205531B2 (en) 2010-01-13 2013-10-10 Amgen Inc. IL-22-Fc and hepcidin activity
LT2010013A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Biologiškai aktyvių granulocitų kolonijas stimuliuojančio faktoriaus darinių išskyrimo ir gryninimo būdas
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用

Also Published As

Publication number Publication date
CN102260343A (zh) 2011-11-30
PT2576624T (pt) 2016-10-31
WO2011147319A1 (en) 2011-12-01
NL301285I2 (nl) 2024-08-21
CN102906120B (zh) 2015-03-04
EP2576624B1 (en) 2016-08-31
US9273108B2 (en) 2016-03-01
HUE031872T2 (en) 2017-08-28
FR24C1032I1 (fr) 2024-08-30
FR24C1032I2 (fr) 2025-06-20
US8557546B2 (en) 2013-10-15
AU2011257734B2 (en) 2015-06-11
CN102906120A (zh) 2013-01-30
FIC20240027I1 (fi) 2024-07-30
JP6114186B2 (ja) 2017-04-12
EP3121198A1 (en) 2017-01-25
EP2576624A4 (en) 2013-11-13
CA2800688A1 (en) 2011-12-01
HUS2400027I1 (hu) 2024-08-28
CA2800688C (en) 2018-05-15
ES2611151T3 (es) 2017-05-05
JP2013530148A (ja) 2013-07-25
US20140004076A1 (en) 2014-01-02
DK2576624T3 (en) 2016-11-14
DK3121198T3 (da) 2019-10-28
EP3121198B1 (en) 2019-08-14
US20110293554A1 (en) 2011-12-01
AU2011257734A1 (en) 2012-12-20
ES2750730T3 (es) 2020-03-26
EP2576624A1 (en) 2013-04-10
CN104710535A (zh) 2015-06-17
CN104710535B (zh) 2018-10-16

Similar Documents

Publication Publication Date Title
HUS2400027I1 (hu) Rekombináns humán G-CSF dimer és alkalmazása, neurológiai betegségek kezelésében
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
IL261742B (en) Human antibodies and their diagnostic and therapeutic uses for the treatment of neurological diseases
IL233832B (en) Agents that induce programmed cell death for the treatment of cancer, immune diseases and immunodeficiency diseases
ZA201208832B (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
IL231702A0 (en) Factors that induce programmed cell death for the treatment of cancer and immune and auto-immune diseases
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
IL221874A (en) History of pyrimidine and their use in the treatment of respiratory diseases such as copd
ZA201301601B (en) Treatment of diseases
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
EP2612676A4 (en) USE OF A G-CSF DIMER IN THE TREATMENT OF NEUTROPENIA
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
IL239078A0 (en) Protein for use in the treatment of eye diseases
SI2555790T1 (sl) Terapevtska uporaba proteina beta2-mikroglobulina
HK1183889A (en) Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases
IL204097A0 (en) Medicine for the treatment of skin cancer